NCT01347346View on ClinicalTrials.gov

Gene Therapy for WAS

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

January 13, 2016

Study Completion Date

January 9, 2017

Conditions
Wiskott-Aldrich Syndrome
Interventions
GENETIC

Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene

transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing human WAS gene

Trial Locations (1)

75015

Hôpital Necker-Enfants Malades, Paris

Sponsors

Lead Sponsor

Genethon
All Listed Sponsors
collaborator

Hôpital Necker-Enfants Malades

OTHER

lead

Genethon

OTHER

NCT01347346 - Gene Therapy for WAS | Biotech Hunter | Biotech Hunter